Showing 651-660 of 9108 results for "".
How Combination Treatments Can Address Unmet Needs
https://practicaldermatology.com/conferences/maui-derm-2024/how-combination-treatments-can-address-unmet-needs/20243/Suneel Chilukuri, MD, talks with Chief Medical Editor Neal Bhatia, MD, about the progress cosmetic dermatology has made to fill previous gaps in options to address areas such as the chest, neck, and knees, especially with the range of advanced devices that often produce even better results when usedHow to Discuss Isotretinoin’s Safety Profile With Acne Patients
https://practicaldermatology.com/conferences/maui-derm-2024/how-to-discuss-isotretinoins-safety-profile-with-acne-patients/20237/Acne Symposium moderator Guy Webster, MD, PhD, clinical professor of dermatology at Thomas Jefferson University, explains how he helps adolescent patients with the most severe cases of acne manage the potential side effects of isotretinoin.DermWireTV: Sotyktu Approval, Cetaphil at 75, Psoriasis/Depression Link
https://practicaldermatology.com/topics/psoriasis/dermwiretv-sotyktu-approval-cetaphil-at-75-psoriasisdepression-link/20138/FDA has approved Bristol Myers Squibb’s Sotyktu (deucravacitinib) for the oral treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. April Armstrong, MD discusses the first TYK-2 inhibitor approved for psoriasis. As Cetaphil (Galderma)AK Burden and Progression Risk
https://practicaldermatology.com/topics/skin-cancer-photoprotection/ak-burden-and-progression-risk/20134/Individuals with chronic sun damage are at higher risk of developing AK lesions. It is therefore essential that dermatologists emphasize early sun protection recommendations and address progression risks of AK with their patients. Faced with increasing burden of skin cancers, Joel L. Cohen, MD and AClinical Conversations: How JAK Inhibitors are Changing the AD Treatment Landscape
https://practicaldermatology.com/series/jak-inhibitors-in-practice/clinical-conversations-how-jak-inhibitors-are-changing-the-ad-treatment-landscape/20092/With the approval of JAK inhibitors to treat eczema, the treatment landscape is changing. Matt Zirwas, MD and Adelaide Hebert, MD talk about the role for JAK inhibitors and key considerations for discussing options with patients.DermWire TV: Adbry Approved; Syringoma Option; Confusion over Vaccines and Injectables
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-adbry-approved-syringoma-option-confusion-over-vaccines-and-injectables/20041/Adbry (tralokinumab) from Leo Pharma is the newest biologic approved for moderate to severe atopic dermatitis in adults and is the first IL-13 blocker approved in the US. Pulse Bioscience’s nano-pulse stimulation (NPS) technology shows potential for the treatment of syringoma in a feasibility studyManaging Patients with Atypical Nevi and Melanoma
https://practicaldermatology.com/topics/skin-cancer-photoprotection/managing-patients-with-atypical-nevi-and-melanoma/19982/Monitoring patients with several atypical nevi who are at high risk for melanoma is very challenging. Steven Q. Wang, MD offers tips for improving diagnostic accuracy and discusses the role of dermoscopy in detecting melanoma as well as non-melanoma skin cancers at much earlier rates.DermWireTV: Cosentyx for Kids; Anifrolumab for SLE, Tremfya in PsA at EULAR
https://practicaldermatology.com/topics/psoriasis/dermwiretv-cosentyx-for-kids-anifrolumab-for-sle-tremfya-in-psa-at-eular/19948/FDA has approved Cosentyx (secukinumab) from Novartis for patients as young as six years old. The 2nd Annual San Diego Dermatology Symposium kicks off as a live Virtual Experience next Friday. A post-hoc analysis of pooled data from the TULIP Phase 3 clinical trials shows that anifrolumab improvesScientifically Speaking: When Accidents Happen in the Surgical/Aesthetic Clinic
https://practicaldermatology.com/topics/practice-management/scientifically-speaking-when-accidents-happen-in-the-surgicalaesthetic-clinic/19906/Surgical and laser procedures bring risks for infections, ocular injury, scarring, and more. In the second of a 2-part series, experts discuss best practices for managing adverse reactions with an emphasis on early intervention. Host Joel L. Cohen, MD leads the conversation with Mathew Avram, MD, JDNew SEO Trends Dermatologists Should Anticipate in 2021
https://practicaldermatology.com/topics/practice-management/new-seo-trends-dermatologists-should-anticipate-in-2021/19900/Dermatology online marketing will have a surge of possible business in 2021 as people start moving back to requesting and seeking medical care again, especially once COVID-19 vaccines become widespread. Getting ahead of the SEO search curve now will give your office the advantage before the demand m